Chicago-based pharmaceutical company Xeris Pharmaceuticals has received patents from both America and China for pre-filled syringe medication development.
"Our strategy as a platform company is to patent early and often to continue to strengthen our position as a product-development and formulation company. These new patent grants represent a significant expansion of Xeris’ intellectual property portfolio and help us to continue to invest in our innovation into life-saving therapies that can benefit patients worldwide," said Xeris Pharmaceuticals Chairman and CEO Paul Edick, according to Business Wire.
Xeris received two patents in the United States. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, with 399 covering the development of storage-stable pramlintide and 403 covering benzodiazepine formulations within the country, according to Business Wire.
The Chinese patent, approved as Patent No. ZL201580042185.5, will allow Xeris to develop pre-filled syringes "containing a variety of active pharmaceutical ingredients" designed to treat a wide array of diseases including diabetes, Business Wire said.
"With the recent opening of our research & development center in Chicago, led by our Chief Scientific Officer and Xeris co-founder Dr. Steve Prestrelski, we anticipate that we will continue to develop and bring to the market novel solutions for treating and preventing a variety of human diseases and disorders, improving the quality of life for our patients and their families," Edick said.
These patents are part of Xeris' ever-growing patent portfolio, bringing the total number of patents granted to Xeris worldwide to 121, with 16 of these patents have been granted in the United States. Xeris currently has 120 patent applications pending worldwide in addition to the three new approvals and expects to receive further patent grants on several of those pending within upcoming months, Business Wire said.
Xeris (Nasdaq: XERS) strives to deliver innovative solutions to simplify the experience of administering important therapies that are depended on every day across the globe.